[Go to the reading](#juv-reading) [What fades](/what-fades/) [Four options](/#four-options) [Compare](/compare/) [The route](/how-it-works/) [Juventa](/) Menu [What fades](/what-fades/) [Four options](/#four-options) [Compare](/compare/) [The route](/how-it-works/) # NAD+ Following the age-related decline in tissue NAD+. 30 40 50 60 70 Age-related decline is gradual. These studies compare age groups; they do not identify a starting age or a treatment deadline. We examine NAD+ as a cell coenzyme, its decline with age and the gap between a changed measurement and a meaningful result from treatment. [Take NAD+ questions to Promise Peptides](https://mypromise.com/products/nad-plus?utm_source=juventa&utm_medium=affiliate&utm_campaign=product&utm_content=nad-plus-opening) Juventa Peptides may earn money when readers become Promise patients. ![A phase-contrast micrograph of a small group of cultured cells with softly visible nuclei.](/juventa-timber-f62c248e90a9/crosscut-in-the-shed.webp) ## Less in tissue, more to understand The full name behind NAD+ is nicotinamide adenine dinucleotide. NAD+ is a coenzyme: it partners with enzymes, proteins that help chemical reactions happen. It participates in the movement of electrons involved in energy chemistry and in processes connected with cellular maintenance. Despite its place beside peptide treatments in many conversations, NAD+ is not a peptide. The body makes its own NAD+. The [aging research](https://pubmed.ncbi.nlm.nih.gov/24360282/) describes lower levels across tissues with age and investigates communication between a cell’s nucleus and mitochondria. The nucleus contains most genetic instructions; mitochondria are structures involved in energy supply. Much of the mechanistic work is in mice and cells, rather than a test of a treatment for an older adult. There is no single implication hidden inside “lower.” The location of a measurement matters, and a blood result is not a direct reading of every tissue. A decline is a reason to investigate biology. It does not establish that administering NAD+ changes a person’s health in a useful way. ## What the human research actually tested An [early human infusion pilot](https://pubmed.ncbi.nlm.nih.gov/31572171/) tracked NAD+ and related breakdown products in blood and urine. A pilot gives researchers a small first look at a question. It can help researchers understand what to measure next, but it cannot establish a long-term clinical benefit. Changes in circulating metabolites, the substances involved in metabolism, are different from evidence of longer life or healthier aging. Another important distinction is the ingredient being studied. A [controlled study of nicotinamide riboside](https://pubmed.ncbi.nlm.nih.gov/29599478/) found higher whole-blood NAD+ in middle-aged and older adults. Nicotinamide riboside is a precursor that the body can use to make NAD+. The trial used a comparison treatment and concealed assignments from participants and researchers. It was not a trial of prescription NAD+ itself. Those findings can sit on the same reading list without being treated as interchangeable. An oral precursor, an infusion and a compounded prescription have different questions around delivery and evidence. A higher blood measurement alone is not a demonstrated improvement in daily life. ## The unanswered part Large, controlled human evidence connecting direct NAD+ treatment with durable aging outcomes is lacking. We cannot infer the right person, the right tissue target or a meaningful long-term result simply from the molecule’s normal role. The body needing a substance is not the same proposition as a person needing more of it by a particular route. ## How to read a personal account **Anecdotal, not clinical evidence.** An impression after a procedure does not contain its own comparison group. Feeling different and knowing why are separate things. Such an account cannot establish that age-related tissue NAD+ was the cause of a concern or that a changed level explains the experience. ## Safety is more than the molecule’s name. The human infusion literature and broader discussion include discomfort, flushing and nausea. Compounded injectable NAD+ also carries concerns about contamination. Its natural role inside cells does not certify the safety of a prepared product or the procedure used to deliver it. NAD+ prepared as a compounded medicine is not FDA-approved. The FDA’s [compounding overview](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) explains why preparation through a pharmacy does not mean premarket verification of the resulting medicine’s safety, effectiveness and quality. Long-term safety in a general aging population remains an open question alongside benefit. ## What needs an individual decision Promise Peptides has a NAD+ treatment page for U.S. prescription inquiries. Its licensed provider reviews the request and may decide against prescribing. NAD+ prepared as a compounded medicine is not FDA-approved; the consultation is an individual medical decision, not confirmation that an age-related decline needs correcting. A discussion can ask what problem is being evaluated, which evidence concerns the proposed preparation and what would count as a worthwhile outcome. A provider’s review belongs around the person’s health history and current concerns. The calendar alone is an unusually thin medical history. ## A question can be the next step. Promise Peptides connects U.S. patients with licensed U.S. providers who examine every request and decide whether prescribing is appropriate. The review may find that a person does not qualify. Access differs with the patient’s state and the treatment. Licensed U.S. compounding pharmacies prepare prescriptions; compounded medicines prepared for these prescriptions are not FDA-approved. [Take NAD+ questions to Promise Peptides](https://mypromise.com/products/nad-plus?utm_source=juventa&utm_medium=affiliate&utm_campaign=product&utm_content=nad-plus-closing) Promise’s LegitScript certification does not give a medicine FDA approval. Juventa provides reading and perspective; it has no clinic, no pharmacy and no shop. [Continue to Promise’s own site](https://mypromise.com/?utm_source=juventa&utm_medium=affiliate&utm_campaign=product&utm_content=nad-plus-footer) [Home](/) [What fades](/what-fades/) [NAD+](/nad-plus/) [MOTS-c](/mots-c/) [Sermorelin](/sermorelin/) [GHK-Cu](/ghk-cu/) [Care route](/how-it-works/) [Compare](/compare/) [Questions](/faq/) [About](/about/) [Contact](/contact/) [References](/references/) Juventa Peptides may earn money when readers become Promise patients. Juventa Peptides is an independent guide and is not Promise Peptides. © 2026 Juventa Peptides [Read this page as Markdown](/nad-plus/index.md)